Association of Postnatal Opioid Exposure and 2-year Neurodevelopmental Outcomes in Infants Undergoing Cardiac Surgery
In this September 10th, 2024 issue of Jack, Dr. Michael Ogburn's study highlights a troubling association between high postnatal opioid exposure and poorer neurodevelopmental outcomes in infants who h...
2 Sep 20248min
Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome
In the September 10, 2024, issue of JACC, the study by Dr. Doron Seeker and colleagues investigates alirocumab's impact on cardiovascular outcomes related to triglyceride levels. Despite effectively l...
2 Sep 20248min
Serial Shock Severity Assessment Within Seventy-Two Hours after Diagnosis: A Cardiogenic Shock Working Group Report
In the September 10, 2024, JACC issue, Dr. Valentin Fuster discusses a pivotal study on cardiogenic shock, revealing that early and frequent reassessment within the first 24 hours is crucial for predi...
2 Sep 202411min
Prediction of Cumulative Exposure to Atherogenic Lipids During Early Adulthood
In the September 10, 2024, JACC issue, Dr. Valentin Fuster highlights a pivotal study showing that a single cholesterol measurement in young adults can predict future cardiovascular risk with remarkab...
2 Sep 202410min
JACC - September 10, 2024 Issue Summary
In the September 10, 2024, issue of JACC, Dr. Valentin Fuster highlights groundbreaking research on lipid exposure in early adulthood and its link to later cardiovascular events, the importance of ear...
2 Sep 202421min
Serial Shock Severity Assessment: Some Answers. Still Many Questions. | ESC 2024
Rasha K. Al-Lamee, MD, PhD, JACC Deputy Editor and Navin K. Kapur MD discuss the work from the Cardiogenic Shock Working Group, which is an academic research consortium comprising ~40 hospitals in the...
31 Aug 202411min
Insights from RESHAPE-HF2 Trial | ESC 2024
Aakriti Gupta, MD, FACC, JACC Executive Associate Editor, and Stefan D. Anker, MD, discuss the insights from the RESHAPE-HF2 trial - an eight-year study on the efficacy of transcatheter edge-to-edge r...
31 Aug 202413min
A Secondary Analysis of DANFLU-1 Trial - High vs Standard Dose Influenza Vaccine in CKD | ESC 2024
Khurram Nasir, MBBS, FACC, JACC Associate Editor and Tor Biering-Sorenson, MD, MPH, PhD, discuss the importance of influenza vaccines for patients with chronic kidney disease (CKD), particularly in th...
31 Aug 202416min
